Condition: Mitral Valve Regurgitation (Degenerative or Functional) · Sponsor: HVR Cardio Oy
Patients with functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are symptomatic (NYHA Class II-IV) will be evaluated for treatment using the CathHELIX Transcatheter Mitral Annuloplasty System.
This description comes directly from the study's public registry record.
Thomas Fleming · 612 940 8037 · tom@hvrcardio.com
Always discuss trial participation with your own doctor first.
| Tbilisi Heart and Vascular Clinic | Tbilisi, Georgia, Georgia | Recruiting |
| Vilnius University Hospital, Santaros Klinikos, Public Institution | Vilnius, Lithuania, Lithuania | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07188233